Related Experiment Video

Updated: May 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

[Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia]

Ana M Bea1, Rocío Mateo-Gallego1, Estíbaliz Jarauta1

  • 1Unidad de Lípidos y Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, IIS Aragón, Universidad de Zaragoza, Zaragoza, España.

Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis
|March 1, 2014
PubMed

Insights

Lipoprotein(a) [Lp(a)] is linked to atherosclerosis in individuals with familial hypercholesterolemia without specific gene mutations (FH-). High Lp(a) levels (>50mg/dL) significantly correlate with increased cardiovascular disease risk in this group.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Biochemistry
  • Genetics

Context:

  • Elevated Lipoprotein(a) [Lp(a)] is a suspected risk factor in hypercholesterolemia.
  • Familial hypercholesterolemia (FH) encompasses genetic conditions affecting cholesterol metabolism.
  • Understanding Lp(a)'s role in different FH phenotypes is crucial for risk stratification.

Purpose:

  • To investigate the association between Lipoprotein(a) [Lp(a)] levels and atherosclerosis.
  • To evaluate Lp(a)'s impact on carotid intima-media thickness (IMT) and cardiovascular disease (CVD) prevalence across distinct hyperlipidemic groups.
  • To differentiate the role of Lp(a) in FH patients with and without identified pathogenic mutations (FH+ vs. FH-).

Summary:

  • A study of 909 individuals (FH+, FCH, FH-) measured plasma lipids, Lp(a), and carotid IMT.
  • Regression analysis revealed Lp(a) was significantly associated with carotid IMT in FH- subjects.
  • Cardiovascular disease was more prevalent in FH- individuals with Lp(a) >50mg/dL.

Impact:

  • Identifies Lipoprotein(a) [Lp(a)] as a significant contributor to atherosclerosis burden in familial hypercholesterolemia patients lacking specific gene mutations (FH-).
  • Highlights elevated Lp(a) levels (>50mg/dL) as a marker for increased cardiovascular disease risk in the FH- population.
  • Provides evidence for targeted risk assessment and potential therapeutic strategies focusing on Lp(a) in specific hypercholesterolemic subgroups.
Abstract

Keywords:
Cardiovascular diseaseCarotid intima-media thicknessEnfermedad cardiovascularGrosor íntima-media carotídeoLipoprotein(a)Lipoproteína(a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.6K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Inflammation01:38

Inflammation

Overview
46.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948